Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting

The paper presents the results of the Osteoarthritis (OA) Expert Council held on September 8, 2019, which was attended by Russian and foreign specialists. The experts considered pharmacological treatment options for OA. The expert meeting resolution states that the treatment of patients with OA should be based on an individual assessment of the patient and on a modern evidence base of therapy efficacy.

Treatment of patients with OA is based on the principles of evidence-based medicine that requires an integrated approach and the need of SYSADOAs prescription. Combined drugs with therapeutic dosages of chondroitin sulfate and glucosamine in the early stages of the disease are available as basic agents. The place of paracetamol in the anesthetic therapy algorithm in OA needs to be clarified. It is also noted that when choosing nonsteroidal anti-inflammatory drugs for OA treatment, it is important to take into account individual patient characteristics and the presence of comorbidities.

1. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Apr 30. pii: S0049-0172(19)30043-5. doi: 10.1016/j.semarthrit.2019.04.008. [Epub ahead of print]

2. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Jul 3. pii: S1063-4584(19)31116-1. doi: 10.1016/j.joca.2019.06.011. [Epub ahead of print]

3. Rebrov AP, Nasonova VA, Yakushin SS, et al. Results of multicenter clinical trial of Structum in Russia. Terapevticheskii arkhiv. 2001;(11):84-7. (In Russ.)

4. Lippiello L. Collagen Synthesis in Tenocytes, Ligament Cells and Chondrocytes Exposed to a Combination of Glucosamine HCl and Chondroitin Sulfate. Evid Based Complement Alternat Med. 2007 Jun;4(2): 219-24. Epub 2006 Dec 1.

5. Clegg et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23; 354(8):795-808.

6. Hochberg MC, Martel-Pelletier J, Monfort J, et al; MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, noninferiority trial versus celecoxib. Ann Rheum Dis. 2016 Jan;75(1):37-44. doi: 10.1136/annrheumdis-2014-206792. Epub 2015 Jan 14.

7. Martel-Pelletier J, Roubille C, Abram F, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015 Mar;74(3):547-56. doi: 10.1136/annrheumdis-2013-203906

8. Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015 May;74(5):851-8. doi: 10.1136/annrheumdis-2013-203954. Epub 2014 Jan 6.

9. Zeng C, Wei J, Li H, et al. Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee. Sci Rep. 2015 Nov 18;5:16827. doi: 10.1038/srep16827.

10. Alekseeva LI, Sharapova EP, Kashevarova NG, et al. Multicenter prospective observational study on ARTHRA MSM Forte and ARTHRA in patients with osteoarthritis of the knee and / or hip joints and/or lower back pain (preliminary results). Trudnyi patsient. 2018;(16):34-41. (In Russ.).

11. Kezlya OP. Combined treatment of osteoarthritis of the knee. Meditsinskie novosti. 2007;(7):85-7. (In Russ.).

12. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population. J Am Coll Cardiol. 2008 Nov 11; 52(20):1628-36. doi: 10.1016/j.jacc.2008.08.041.

13. McGettiganP, HenryD. CardiovascularRiskwithNon-SteroidalAnti-InflammatoryDrugs: SystematicReviewofPopulation-BasedControlledObservational Studies. PLoS Med. 2011 Sep;8(9):e1001098. doi: 10.1371/journal.pmed.1001098. Epub 2011 Sep 27.